The changing landscape of HIV-associated kidney disease.

UNAIDS. In Danger: UNAIDS Global AIDS Update 2022 https://www.unaids.org/en/resources/documents/2022/in-danger-global-aids-update (Joint United Nations Programme on HIV/AIDS, 2022).

Rao, T. K. et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N. Engl. J. Med. 310, 669–673 (1984).

pubmed: 6700641 doi: 10.1056/NEJM198403153101101

D’Agati, V., Suh, J. I., Carbone, L., Cheng, J. T. & Appel, G. Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. Kidney Int. 35, 1358–1370 (1989).

pubmed: 2770114 doi: 10.1038/ki.1989.135

Kudose, S. et al. The spectrum of kidney biopsy findings in HIV-infected patients in the modern era. Kidney Int. 97, 1006–1016 (2020).

pubmed: 32278618 doi: 10.1016/j.kint.2020.01.018

Diana, N. E. et al. Clinicopathological correlation of kidney disease in HIV infection pre- and post-ART rollout. PLoS One 17, e0269260 (2022).

pubmed: 35639767 pmcid: 9154109 doi: 10.1371/journal.pone.0269260

Achhra, A. C. et al. Impact of early versus deferred antiretroviral therapy of estimated glomerular filtration rate in HIV-positive individuals in the START trial. Int. J. Antimicrob. Agents 50, 453–460 (2017).

pubmed: 28668686 pmcid: 5581703 doi: 10.1016/j.ijantimicag.2017.04.021

Stock, P. G. et al. Outcomes of kidney transplantation in HIV-infected recipients. N. Engl. J. Med. 18, 363 (2010). Erratum in: N Engl J Med. 364, 1082 (2011).

Muller, E. et al. Kidney transplantation in HIV-positive patients: current practice and management strategies. Transplantation 105, 1492–1501 (2021).

pubmed: 33044431 pmcid: 8026768 doi: 10.1097/TP.0000000000003485

Kimmel, P. L., Barisoni, L. & Kopp, J. B. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann. Intern. Med. 139, 214–226 (2003).

pubmed: 12899589 doi: 10.7326/0003-4819-139-3-200308050-00011

Lescure, F. X. et al. HIV-associated kidney glomerular diseases: changes with time and HAART. Nephrol. Dial. Transpl. 27, 2349–2355 (2012).

doi: 10.1093/ndt/gfr676

Swanepoel, C. R. et al. Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 93, 545–559 (2018).

pubmed: 29398134 pmcid: 5983378 doi: 10.1016/j.kint.2017.11.007

Wearne, N. et al. The evolving spectrum of kidney histology in HIV positive patients in South Africa. Kidney Int. Rep. 8, 1087–1096 (2023).

pubmed: 37180521 pmcid: 10166739 doi: 10.1016/j.ekir.2023.02.1076

Mallipattu, S. K., Salem, F. & Wyatt, C. M. The changing epidemiology of HIV-related chronic kidney disease in the era of antiretroviral therapy. Kidney Int. 86, 259–265 (2014).

pubmed: 24573317 doi: 10.1038/ki.2014.44

Wyatt, C. M., Klotman, P. E. & DÁgati, V. D. HIV-associated nephropathy: clinical presentation, pathology and epidemiology in the era of antiretroviral therapy. Semin. Nephrol. 28, 513–522 (2008).

pubmed: 19013322 pmcid: 2656916 doi: 10.1016/j.semnephrol.2008.08.005

Alfano, G. et al. Kidney disease in HIV infection. J. Clin. Med. 8, 1254 (2019).

pubmed: 31430930 pmcid: 6722524 doi: 10.3390/jcm8081254

Remark, R. et al. In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. Sci. Immunol. 1, aaf6925 (2016).

pubmed: 28783673 pmcid: 10152404 doi: 10.1126/sciimmunol.aaf6925

Xu, G. J. et al. Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. Science 348, aaa0698 (2015).

pubmed: 26045439 pmcid: 4844011 doi: 10.1126/science.aaa0698

Kimmel, P. L. et al. Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N. Engl. J. Med. 327, 702–706 (1992).

pubmed: 1495523 doi: 10.1056/NEJM199209033271006

Kimmel, P. L. et al. HIV-associated immune-mediated renal disease. Kidney Int. 44, 1327–1340 (1993).

pubmed: 8301934 doi: 10.1038/ki.1993.386

Gerntholtz, T. E., Goetsch, S. J. & Katz, I. HIV-related nephropathy: a South African perspective. Kidney Int. 69, 1885–1891 (2006).

pubmed: 16625149 doi: 10.1038/sj.ki.5000351

Vermeulen, A. et al. Patterns of renal disease: a 30-year renal biopsy study at Chris Hani Baragwanath Academic Hospital, Soweto, Johannesburg, South Africa. S Afr. Med. J. 109, 486–492 (2019).

pubmed: 31266574 doi: 10.7196/SAMJ.2019.v109i7.13644

Nair, R., Walker, P. D. & Is, I. G. A nephropathy the commonest primary glomerulopathy among your adults in the USA? Kidney Int. 69, 1455–1458 (2006).

pubmed: 16531983 doi: 10.1038/sj.ki.5000292

Fabrizi, F. et al. Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: systematic review and meta-analysis. J. Med. Virol. 88, 487–497 (2016).

pubmed: 26271205 doi: 10.1002/jmv.24353

Mocroft, A. et al. Hepatitis B and co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One 7, e40245 (2012).

pubmed: 22911697 pmcid: 3401192 doi: 10.1371/journal.pone.0040245

Davidson, B. et al. Granulomatous interstitial nephritis on renal biopsy in human immunodeficiency virus positive patients: prevalence and causes in Cape Town, South Africa. Nephrology 24, 681–688 (2019).

pubmed: 30663206 doi: 10.1111/nep.13564

Kearns, A., Gordon, J., Burdo, T. H. & Qin, X. HIV-1-associated atherosclerosis: unraveling the missing link. J. Am. Coll. Cardiol. 69, 3084–3098 (2017).

pubmed: 28641798 pmcid: 5512584 doi: 10.1016/j.jacc.2017.05.012

Ipp, H. & Zemlin, A. The paradox of the immune response in HIV infection: when inflammation becomes harmful. Clin. Chim. Acta 416, 96–99 (2013).

pubmed: 23228847 doi: 10.1016/j.cca.2012.11.025

Kelesidis, T., Kendall, M. A., Yang, O. O., Hodis, H. N. & Currier, J. S. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J. Infect. Dis. 206, 1558–1567 (2012).

pubmed: 23066162 pmcid: 3475633 doi: 10.1093/infdis/jis545

Alcaide, M. L. et al. Immune activation in HIV-infected aging women on antiretrovirals-implications for age-associated comorbidities: a cross-sectional pilot study. PLoS One 8, e63804 (2013).

pubmed: 23724003 pmcid: 3665816 doi: 10.1371/journal.pone.0063804

Ma, R., Yang, L., Niu, F. & Buch, S. HIV Tat-mediated induction of human brain microvascular endothelial cell apoptosis involves endoplasmic reticulum stress and mitochondrial dysfunction. Mol. Neurobiol. 53, 132–142 (2016).

pubmed: 25409632 doi: 10.1007/s12035-014-8991-3

Guo, H., Gao, J., Taxman, D. J., Ting, J. P. & Su, L. HIV-1 infection induces interleukin-1β production via TLR8 protein-dependent and NLRP3 inflammasome mechanisms in human monocytes. J. Biol. Chem. 289, 21716–21726 (2014).

pubmed: 24939850 pmcid: 4118130 doi: 10.1074/jbc.M114.566620

Hernandez, J. C., Latz, E. & Urcuqui-Inchima, S. HIV-1 induces the first signal to activate the NLRP3 inflammasome in monocyte-derived macrophages. Intervirology 57, 36–42 (2014).

pubmed: 24008203 doi: 10.1159/000353902

Brown, T. T. et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch. Intern. Med. 165, 1179–1184 (2005).

pubmed: 15911733 doi: 10.1001/archinte.165.10.1179

Heron, J. E. et al. The prevalence and risk of non-infectious comorbidities in HIV infected and non-HIV infected men attending general practice in Australia. PLoS One 14, e0223224 (2019).

pubmed: 31596867 pmcid: 6784917 doi: 10.1371/journal.pone.0223224

Høgh, J. et al. HIV infection as associated with type 2 diabetes mellitus. J. Acquir. Immune Defic. Syndr. 88, e32–e35 (2021).

pubmed: 34520442 doi: 10.1097/QAI.0000000000002798

Noubissi, E. C., Katte, J. C. & Sobngwi, E. Diabetes and HIV. Curr. Diab Rep. 18, 125 (2018).

pubmed: 30294763 doi: 10.1007/s11892-018-1076-3

Mallipattu, S. K. et al. Expression of HIV transgene aggravates kidney injury in diabetic mice. Kidney Int. 83, 626–634 (2013).

pubmed: 23325078 pmcid: 3612382 doi: 10.1038/ki.2012.445

Gooden, T. E. et al. A matched cohort study investigating premature, accentuated, and accelerated aging in people living with HIV. HIV Med. 24, 640–647 (2023).

pubmed: 35934808 doi: 10.1111/hiv.13375

Cohen, S. & Kimmel, P. Renal biopsy is necessary for the diagnosis of HIV-associated renal diseases. Nat. Rev. Nephrol. 5, 22–23 (2009).

doi: 10.1038/ncpneph0990

Soler-García, A. A., Rakhmanina, N. Y., Mattison, P. C. & Ray, P. E. A urinary biomarker profile for children with HIV-associated renal diseases. Kidney Int. 76, 207–214 (2009).

pubmed: 19357719 pmcid: 2778294 doi: 10.1038/ki.2009.115

Paragas, N. et al. Urinary NGAL marks cystic disease in HIV-associated nephropathy. J. Am. Soc. Nephrol. 20, 1687–1692 (2009).

pubmed: 19628667 pmcid: 2723987 doi: 10.1681/ASN.2009010065

Sola-Del Valle, D. A. et al. Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy. Nephrol. Dial. Transpl. 26, 2387–2390 (2011).

doi: 10.1093/ndt/gfr258

Naicker, S. et al. Profiling biomarkers in HIV glomerular disease — potential for the non-invasive diagnosis of HIVAN? Int. J. Nephrol. Renovasc Dis. 14, 427–440 (2021).

pubmed: 34916827 pmcid: 8668162 doi: 10.2147/IJNRD.S331484

Griffin, B. R., Faubel, S. & Edelstein, C. L. Biomarkers of drug-induced kidney toxicity. Ther. Drug. Monit. 41, 213–226 (2019).

pubmed: 30883514 pmcid: 6436396 doi: 10.1097/FTD.0000000000000589

Fiseha, T. & Gebreweld, A. Urinary markers of tubular injury in HIV-infected patients. Biochem. Res. Int. 2016, 1501785 (2016).

pubmed: 27493802 pmcid: 4967446 doi: 10.1155/2016/1501785

Shlipak, M. G. et al. Urinary markers of kidney injury and kidney function decline in HIV-infected women. J. Acquir. Immune Defic. Syndr. 61, 565–573 (2012).

pubmed: 23023103 pmcid: 3509242 doi: 10.1097/QAI.0b013e3182737706

Inker, L. A. et al. Performance of creatinine and cystatin C GFR estimating equations in an HIV population on antiretrovirals. J. Acquir. Immune Defic. Syndr. 61, 302–309 (2012).

pubmed: 22842844 pmcid: 3598619 doi: 10.1097/QAI.0b013e31826a6c4f

Gagneux-Brunon, A. et al. Performance of creatinine and cystatin C-based glomerular filtration rate estimation equations in a European HIV-positive cohort. AIDS 27, 1573–1581 (2013).

pubmed: 23435293 doi: 10.1097/QAD.0b013e32835fac30

European AIDS Clinical Society guidelines Oct 2021. https://www.eacsociety.org/guidelines/eacs-guidelines/ (accessed January 2023).

Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med 150, 604–612 (2009).

pubmed: 19414839 pmcid: 2763564 doi: 10.7326/0003-4819-150-9-200905050-00006

Degado, C. et al. Reassessing the inclusion of race in diagnosing kidney diseases: an interim report from the NKF-ASN Task Force. Am. J. Kidney Dis. 78, 103–115 (2021).

doi: 10.1053/j.ajkd.2021.03.008

Degado, C. et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. Am. J. Kidney Dis. 79, 268–288.e1 (2022).

doi: 10.1053/j.ajkd.2021.08.003

Muiru, A. N. et al. Effect of adopting the new race-free 2021 chronic kidney disease epidemiology collaboration estimated glomerular filtration rate creatinine equation on racial differences in kidney disease progression among people with human immunodeficiency virus: an observational study. Clin. Infect. Dis. 76, 461–468 (2023).

pubmed: 36069064 doi: 10.1093/cid/ciac731

Fabian, J. et al. Measurement of kidney function in Malawi, South Africa, and Uganda: a multicenter cohort study. Lancet Glob. Health 10, e1159–e1169 (2022).

pubmed: 35839814 doi: 10.1016/S2214-109X(22)00239-X

Inker, L. A. et al. New creatinine-and cystatin C–based equations to estimate GFR without race. N. Engl. J. Med. 385, 1737–1749 (2021).

pubmed: 34554658 pmcid: 8822996 doi: 10.1056/NEJMoa2102953

Bhasin, B. et al. Correction: HIV viremia and T-cell activation differentially affect the performance of glomerular filtration rate equations based on creatinine and cystatin C. PLoS One 14, e0215630 (2019).

pubmed: 30990858 pmcid: 6467568 doi: 10.1371/journal.pone.0215630

Bruggeman, L. A. et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J. Am. Soc. Nephrol. 11, 2079–2087 (2000).

pubmed: 11053484 doi: 10.1681/ASN.V11112079

Marras, D. et al. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat. Med. 8, 522–526 (2002).

pubmed: 11984599 doi: 10.1038/nm0502-522

Payne, E. H., Ramalingam, D., Fox, D. T. & Klotman, M. E. Polyploidy and mitotic cell death are two distinct HIV-1 Vpr-driven outcomes in renal tubule epithelial cells. J. Virol. 92, e01718–17 (2018).

pubmed: 29093088 pmcid: 5752950 doi: 10.1128/JVI.01718-17

Bruggeman, L. A. et al. Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J. Clin. Invest. 100, 84–92 (1997).

pubmed: 9202060 pmcid: 508168 doi: 10.1172/JCI119525

Husain, M. et al. HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J. Am. Soc. Nephrol. 13, 1806–1815 (2002).

pubmed: 12089376 doi: 10.1097/01.ASN.0000019642.55998.69

Dickie, P. et al. HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology 185, 109–119 (1991).

pubmed: 1926769 doi: 10.1016/0042-6822(91)90759-5

Zuo, Y. et al. HIV-1 genes vpr and nef synergistically damage podocytes, leading to glomerulosclerosis. J. Am. Soc. Nephrol. 17, 2832–2843 (2006).

pubmed: 16988066 doi: 10.1681/ASN.2005080878

Conaldi, P. G. et al. Human immunodeficiency virus-1 tat induces hyperproliferation and dysregulation of renal glomerular epithelial cells. Am. J. Pathol. 61, 53–61 (2002).

doi: 10.1016/S0002-9440(10)64156-9

Winston, J. A. et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N. Engl. J. Med. 344, 1979–1984 (2001).

pubmed: 11430327 doi: 10.1056/NEJM200106283442604

Pierson, T., McArthur, J. & Siliciano, R. F. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu. Rev. Immunol. 18, 665–708 (2000).

pubmed: 10837072 doi: 10.1146/annurev.immunol.18.1.665

Cohen, A. H., Sun, N. C., Shapshak, P. & Imagawa, D. T. Demonstration of human immunodeficiency virus in renal epithelium in HIV-associated nephropathy. Mod. Pathol. 2, 125–128 (1989).

pubmed: 2657719

Blasi, M. et al. Identification of HIV-1 genitourinary tract compartmentalization by analyzing the env gene sequences in urine. AIDS 29, 1651–1657 (2015).

pubmed: 26372275 doi: 10.1097/QAD.0000000000000757

Mzingwane, M. L. et al. Detection and molecular characterization of urinary tract HIV-1 populations. Ann. Clin. Microbiol. Antimicrob. 18, 27 (2019).

pubmed: 31551072 pmcid: 6760049 doi: 10.1186/s12941-019-0326-9

Canaud, G. et al. The kidney as a reservoir for HIV-1 after renal transplantation. J. Am. Soc. Nephrol. 25, 407–419 (2014).

pubmed: 24309185 doi: 10.1681/ASN.2013050564

Blasi, M. et al. Detection of donor’s HIV strain in HIV-positive kidney transplant recipient. N. Engl. J. Med. 382, 195–197 (2020).

pubmed: 31914248 pmcid: 7135441 doi: 10.1056/NEJMc1910189

Dufour, C. et al. Near full-length HIV sequencing in multiple tissues collected postmortem reveals shared clonal expansions across distinct reservoirs during ART. Cell Rep. 42, 113053 (2023).

pubmed: 37676762 doi: 10.1016/j.celrep.2023.113053

Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841–845 (2010).

pubmed: 20647424 pmcid: 2980843 doi: 10.1126/science.1193032

Tzur, S. et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum. Genet. 128, 345–350 (2010).

pubmed: 20635188 pmcid: 2921485 doi: 10.1007/s00439-010-0861-0

Daneshpajouhnejad, P., Kopp, J. B., Winkler, C. A. & Rosenberg, A. Z. The evolving story of apolipoprotein L1 nephropathy: the end of the beginning. Nat. Rev. Nephrol. 18, 307–320 (2022).

pubmed: 35217848 pmcid: 8877744 doi: 10.1038/s41581-022-00538-3

Dummer, P. D. et al. APOL1 kidney disease risk variants: an evolving landscape. Semin. Nephrol. 35, 222–236 (2015).

pubmed: 26215860 pmcid: 4562465 doi: 10.1016/j.semnephrol.2015.04.008

Kopp, J. B. et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 22, 2129–2137 (2011).

pubmed: 21997394 pmcid: 3231787 doi: 10.1681/ASN.2011040388

Kasembeli, A. N. et al. APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans. J. Am. Soc. Nephrol. 26, 2882–2890 (2015).

pubmed: 25788523 pmcid: 4625661 doi: 10.1681/ASN.2014050469

Atta, M. G. et al. Association of APOL1 genotype with renal histology among black HIV-positive patients undergoing kidney biopsy. Clin. J. Am. Soc. Nephrol. 11, 262–270 (2016).

pubmed: 26668025 doi: 10.2215/CJN.07490715

Abdu, A. et al. High risk APOL1 genotypes and kidney disease among treatment naïve HIV patients at Kano, Nigeria. PLoS One 17, e0275949 (2022).

pubmed: 36227935 pmcid: 9560498 doi: 10.1371/journal.pone.0275949

Hung, R. K. Y. et al. Genetic variants of APOL1 are major determinants of kidney failure in people of African ancestry with HIV. Kidney Int. Rep. 7, 786–796 (2022).

pubmed: 35497797 pmcid: 9039486 doi: 10.1016/j.ekir.2022.01.1054

Waziri, B., Raji, Y. E., Ekrikpo, U. E. & Naicker, S. Apolipoprotein L1 gene variants and kidney disease in patients with HIV: a systematic review and meta-analysis. J. Nephrol. 36, 1119–1134 (2023).

pubmed: 36510118 doi: 10.1007/s40620-022-01512-9

Fine, D. M. et al. APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease. J. Am. Soc. Nephrol. 23, 343–350 (2012).

pubmed: 22135313 pmcid: 3269183 doi: 10.1681/ASN.2011060562

Purswani et al. Pediatric HIVAIDS Cohort Study. Brief report: APOL1 renal risk variants are associated with chronic kidney disease in children and youth with perinatal HIV infection. J. Acquir. Immune Defic. Syndr. 73, 63–68 (2016).

pubmed: 27035887 pmcid: 4981510 doi: 10.1097/QAI.0000000000001010

Ekulu, P. M. et al. APOL1 risk genotypes are associated with early kidney damage in children in Sub-Saharan Africa. Kidney Int. Rep. 4, 930–938 (2019).

pubmed: 31317115 pmcid: 6612006 doi: 10.1016/j.ekir.2019.04.002

Behar, D. M. et al. Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population. Am. J. Nephrol. 34, 452–459 (2011).

pubmed: 21968148 doi: 10.1159/000332378

Rosset, S., Tzur, S., Behar, D. M., Wasser, W. G. & Skorecki, K. The population genetics of chronic kidney disease: insights from the MYH9-APOL1 locus. Nat. Rev. Nephrol. 7, 313–326 (2011).

pubmed: 21537348 doi: 10.1038/nrneph.2011.52

Johnstone, D. B. et al. APOL1 null alleles from a rural village in India do not correlate with glomerulosclerosis. PLoS One 7, e51546 (2012).

pubmed: 23300552 pmcid: 3530541 doi: 10.1371/journal.pone.0051546

Friedman, D. J. A brief history of APOL1: a gene evolving. Semin. Nephrol. 37, 508–513 (2017).

pubmed: 29110757 doi: 10.1016/j.semnephrol.2017.07.003

Olabisi, O. A. et al. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. Proc. Natl Acad. Sci. USA 113, 830–837 (2016).

pubmed: 26699492 doi: 10.1073/pnas.1522913113

Rednor, S. J. & Ross, M. J. Molecular mechanisms of injury in HIV-associated nephropathy. Front. Med. 5, 177 (2018).

doi: 10.3389/fmed.2018.00177

Beckerman, P. et al. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. Nat. Med. 23, 429–438 (2017).

pubmed: 28218918 pmcid: 5603285 doi: 10.1038/nm.4287

McCarthy, G. M. et al. Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease. Dis. Model. Mech. 14, dmm048952 (2021).

pubmed: 34350953 pmcid: 8353097 doi: 10.1242/dmm.048952

Kalayjian, R. C. The treatment of HIV-associated nephropathy. Adv. Chronic Kidney Dis. 17, 59–71 (2010).

pubmed: 20005490 pmcid: 2811489 doi: 10.1053/j.ackd.2009.08.013

Estrella, M. M. et al. The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status. Clin. Infect. Dis. 60, 646–652 (2015).

pubmed: 25281610 doi: 10.1093/cid/ciu765

Freedman, B. I. & Skorecki, K. Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy. Clin. J. Am. Soc. Nephrol. 9, 2006–2013 (2014).

pubmed: 24903390 pmcid: 4220749 doi: 10.2215/CJN.01330214

Danwang, C., Noubiap, J. J., Robert, A. & Yombi, J. C. Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis. AIDS Res. Ther. 19, 3 (2022).

pubmed: 35031068 pmcid: 8759058 doi: 10.1186/s12981-021-00427-y

Bertagnolio, S. et al. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet HIV. 9, e486–e495 (2022).

pubmed: 35561704 pmcid: 9090268 doi: 10.1016/S2352-3018(22)00097-2

May, R. M. et al. A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19). Kidney Int. 100, 1303–1315 (2021).

pubmed: 34352311 pmcid: 8328528 doi: 10.1016/j.kint.2021.07.015

Velez, J. C., Caza, T. & Larsen, C. COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nat. Rev. Nephrol. 16, 565–567 (2020).

pubmed: 32753739 pmcid: 7400750 doi: 10.1038/s41581-020-0332-3

Shetty, A. A. et al. COVID-19-associated glomerular disease. J. Am. Soc. Nephrol. 32, 33 (2021).

pubmed: 33214201 doi: 10.1681/ASN.2020060804

Wu, H. L. et al. Acute kidney injury and collapsing glomerulopathy associated with COVID-19 and APOL1 high risk genotype. J. Am. Soc. Nephrol. 31, 1688–1695 (2020).

pubmed: 32561682 pmcid: 7460910 doi: 10.1681/ASN.2020050558

Giannini, G. et al. Renal prognosis of COVID-19 associated nephropathy. Kidney Int. Rep. 7, 2722–2725 (2022).

pubmed: 36277848 pmcid: 9579006 doi: 10.1016/j.ekir.2022.09.027

Kudose, S. et al. Longitudinal outcomes of COVID-19-associated collapsing glomerulopathy and other podocytopathies. J. Am. Soc. Nephrol. 32, 2958–2969 (2021).

pubmed: 34670811 pmcid: 8806099 doi: 10.1681/ASN.2021070931

World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. https://www.who.int/publications/i/item/9789240031593 (World Health Organization, 2021; accessed January 2023).

Acquah, R., Graham, H. & Winter, A. Quantifying polypharmacy in a large HIV-infected cohort. HIV Med. 16, 583–584 (2015).

pubmed: 26331609 doi: 10.1111/hiv.12296

Bastida, C. et al. Polypharmacy and potential drug-drug interactions in an HIV-infected elderly population. Farm. Hosp. 41, 618–624 (2017).

pubmed: 28847251

Cohen, S. D., Kopp, J. B. & Kimmel, P. L. Kidney diseases associated with human immunodeficiency virus infection. N. Engl. J. Med. 14, 377 (2017). Erratum in: N. Engl. J. Med. 378, 1657 (2018).

Hamzah, L. et al. Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate. J. Infect. 74, 492–500 (2017).

pubmed: 28130143 doi: 10.1016/j.jinf.2017.01.010

Irizarry-Alvarado, J. M., Dwyer, J. P., Brumble, L. M., Alvarez, S. & Mensez, J. C. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. AIDS Read. 19, 114–121 (2009).

pubmed: 19334328

Iwata, K., Nagata, M., Watanabe, S. & Nishi, S. Distal renal tubular acidosis without renal impairment after use of tenofovir: a case report. BMC Pharm. Toxicol. 17, 52 (2016).

doi: 10.1186/s40360-016-0100-y

Fernandez-Fernandez, B. et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res. Treat. 2011, 354908 (2011).

pubmed: 21716719 pmcid: 3119412

Mocroft, A. et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international Cohort Study. Lancet HIV. 3, e23–e32 (2016).

pubmed: 26762990 doi: 10.1016/S2352-3018(15)00211-8

Cooper, R. D. et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin. Infect. Dis. 51, 496–505 (2010).

pubmed: 20673002 doi: 10.1086/655681

Stray, K. M. et al. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures. Antivir. Res. 140, 116–120 (2017).

pubmed: 28131805 doi: 10.1016/j.antiviral.2017.01.014

Novick, T. K. et al. Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: a case report. Medicine 96, e8046 (2017).

pubmed: 28885375 pmcid: 6393094 doi: 10.1097/MD.0000000000008046

Bahr, N. C. & Yarlagadda, S. G. Fanconi syndrome and tenofovir alafenamide: a case report. Ann. Intern. Med. 170, 814 (2019).

pubmed: 30690644 doi: 10.7326/L18-0592

Post, F. A. et al. Brief report: switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study. J. Acquir. Immune Defic. Syndr. 74, 180 (2017).

pubmed: 27673443 pmcid: 5228610 doi: 10.1097/QAI.0000000000001186

Pilkington, V. et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14894 patients across 14 trials. AIDS 34, 2259–2268 (2020).

pubmed: 33048869 doi: 10.1097/QAD.0000000000002699

Burgos, J., Ribera, E. & Falco, V. Antiretroviral therapy in advanced HIV disease: which is the best regimen? AIDS Rev. 20, 3–13 (2018).

pubmed: 29369304 doi: 10.24875/AIDSRev.M17000010

Achhra, A. C., Nugent, M., Mocroft, A., Ryom, L. & Wyatt, C. M. Chronic kidney disease and antiretroviral therapy in HIV-positive individuals: recent developments. Curr. HIV/AIDS Rep. 13, 149–157 (2016).

pubmed: 27130284 doi: 10.1007/s11904-016-0315-y

Chughlay, M. F. et al. Acute interstitial nephritis caused by lopinavir/ritonavir in a surgeon receiving antiretroviral postexposure prophylaxis. AIDS 29, 503–504 (2015).

pubmed: 25628258 doi: 10.1097/QAD.0000000000000563

Hamada, Y. et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin. Infect. Dis. 55, 1262–1269 (2012).

pubmed: 22820542 doi: 10.1093/cid/cis621

Schmid, S. et al. Acute interstitial nephritis of HIV positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. Virchows Arch. 450, 665–670 (2007).

pubmed: 17464512 doi: 10.1007/s00428-007-0418-3

Jose, S. et al. Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir. AIDS 31, 485–492 (2017).

pubmed: 28121667 doi: 10.1097/QAD.0000000000001353

Gupta, S. K., Mi, D., Moe, S. M., Dubé, M. P. & Liu, Z. Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial. J. Acquir. Immune Defic. Syndr. 64, 279–283 (2013).

pubmed: 24278992 pmcid: 4091630 doi: 10.1097/QAI.0b013e3182a97c39

Milburn, J., Jones, R. & Levy, J. B. Renal effects of novel antiretroviral drugs. Nephrol. Dial. Transpl. 32, 434–439 (2016).

Deeks, E. D. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs 74, 195–206 (2014).

pubmed: 24343782 doi: 10.1007/s40265-013-0160-x

Spagnuolo, V., Castagna, A. & Lazzarin, A. Bictegravir. Curr. Opin. HIV AIDS 13, 326–333 (2018).

pubmed: 29746268 doi: 10.1097/COH.0000000000000468

Yin, J. & Wang, J. Renal drug transporters and their significance in drug–drug interactions. Acta Pharm. Sin. B 6, 363–373 (2016).

pubmed: 27709005 pmcid: 5045553 doi: 10.1016/j.apsb.2016.07.013

Raffi, F. et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 381, 735–743 (2013).

pubmed: 23306000 doi: 10.1016/S0140-6736(12)61853-4

Galizzi, N. et al. Glomerular filtration rate estimated by cystatin C formulas in HIV-1 patients treated with dolutegravir, rilpivirine or cobicistat. N. Microbiol. 41, 256–261 (2018).

Gallant, J. E. et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 354, 251–260 (2006).

pubmed: 16421366 doi: 10.1056/NEJMoa051871

Cutrell, J. & Bedimo, R. Single-tablet regimens in the treatment of HIV-1 infection. Fed. Pract. 33, 24S–30S (2016).

pubmed: 30766212 pmcid: 6375416

Truong, W. R., Schafer, J. J. & Short, W. R. Once-daily, single-tablet regimens for the treatment of HIV-1 infection. P T 40, 44–55 (2015).

pubmed: 25628507 pmcid: 4296592

Michienzi, S. M., Schriever, C. A. & Badowski, M. E. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis. Int. J. STD AIDS 30, 181–187 (2019).

pubmed: 30381029 doi: 10.1177/0956462418800865

Eron, J. J. et al. Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3B trial. Lancet HIV. 6, e15–e24 (2019).

doi: 10.1016/S2352-3018(18)30296-0

Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new (accessed March 2023).

Cahn, P. et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. J. Acquir. Immune Defic. Syndr. 83, 310–318 (2020). Erratum in: J Acquir Immune Defic Syndr. 84, e21 (2020).

pubmed: 31834000 doi: 10.1097/QAI.0000000000002275

van Welzen, B. J., Oomen, P. G. A. & Hoepelman, A. I. M. Dual antiretroviral therapy-all quiet beneath the surface? Front. Immunol. 12, 12 (2021).

Pérez-González, A., Suárez-García, I., Ocampo, A. & Poveda, E. Two-drug regimens for HIV-current evidence, research gaps and future challenges. Microorganisms 10, 433 (2022).

pubmed: 35208887 pmcid: 8880461 doi: 10.3390/microorganisms10020433

Palmer, C. S. et al. Emerging role and characterization of immunometabolism: relevance to HIV pathogenesis, serious non-AIDS events, and a cure. J. Immunol. 196, 4437–4444 (2016).

pubmed: 27207806 doi: 10.4049/jimmunol.1600120

Greene, M., Steinman, M. A., McNicholl, I. R. & Valcour, V. Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. J. Am. Geriatr. Soc. 62, 447–453 (2014).

pubmed: 24576251 pmcid: 4043391 doi: 10.1111/jgs.12695

Wei, A. et al. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int. 64, 1462–1471 (2003).

pubmed: 12969167 doi: 10.1046/j.1523-1755.2003.00230.x

Wheeler, D. C. et al. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrol. Dial. Transpl. 37, 1647–1656 (2022).

doi: 10.1093/ndt/gfab335

Lipkowitz, M. S. et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int. 83, 114–120 (2013).

pubmed: 22832513 doi: 10.1038/ki.2012.263

Freedman, B. I. & Cohen, A. H. Hypertension-attributed nephropathy: what’s in a name? Nat. Rev. Nephrol. 12, 27–36 (2016).

pubmed: 26553514 doi: 10.1038/nrneph.2015.172

Friedman, D. J., Ma, L. & Freedman, B. I. Treatment potential in APOL1-associated nephropathy. Curr. Opin. Nephrol. Hypertens. 31, 442–448 (2022).

pubmed: 35894278 doi: 10.1097/MNH.0000000000000816

Zimmerman B., Dakin L., Fortier A. Small molecule APOL1 inhibitors block APOL1 pore function and reduce proteinuria in an APOL1-mediated kidney disease mouse model. J. Am. Soc. Nephrol. 2021. (Kidney Week Edition Abstract):419.

Egbuna, O. et al. Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants. N. Engl. J. Med. 388, 969–979 (2023).

pubmed: 36920755 doi: 10.1056/NEJMoa2202396

Falk, R. et al. Design of a phase 2/3 adaptive trail, AMPLITUDE, evaluating Inaxaplin in APOL1-mediated kidney disease. J. Am. Soc. Nephrol. (Suppl.) 33, Th-PO480 (2022).

Nichols, B. et al. Innate immunity pathways regulate the nephropathy gene apolipoprotein L1. Kidney Int. 87, 332–342 (2015).

pubmed: 25100047 doi: 10.1038/ki.2014.270

Bruggeman, L. A., Sedor, J. R. & O’Toole, J. F. Apolipoprotein L1 and mechanisms of kidney disease susceptibility. Curr. Opin. Nephrol. Hypertens. 30, 317–323 (2021).

pubmed: 33767059 pmcid: 8211384 doi: 10.1097/MNH.0000000000000704

Singh, J. A. Filgotinib, a JAK1 inhibitor, for treatment-resistant rheumatoid arthritis. JAMA 322, 309–311 (2019).

pubmed: 31334773 doi: 10.1001/jama.2019.9056

Aghajan, M. et al. Antisense oligonucleotide treatment ameliorates IFN-g-induced proteinuria in APOL1-transgenic mice. JCI Insight 4, e126124 (2019).

pubmed: 31217349 pmcid: 6629101 doi: 10.1172/jci.insight.126124

Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS). Organ procurement and transplantation: implementation of the HIV Organ Policy Equity Act. Final rule. Fed. Regist. 80, 26464–26467 (2015).

pubmed: 25985481

Roland, M. E. et al. Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls. AIDS 30, 435–444 (2016).

pubmed: 26765937

Zheng, X. et al. Kidney transplant outcomes in HIV-positive patients: a systematic review and meta-analysis. AIDS Res. Ther. 16, 37 (2019).

pubmed: 31747972 pmcid: 6868853 doi: 10.1186/s12981-019-0253-z

Zarinsefat et al. Long-term outcomes following kidney and liver transplant in recipients with HIV. JAMA Surg. 157, 240–247 (2022). Erratum in: JAMA Surg. (2022).

pubmed: 34985513 pmcid: 8733865 doi: 10.1001/jamasurg.2021.6798

Xia, Y. et al. Effect of HCV, HIV and coinfection in kidney transplant recipients: mate kidney analyses. Am. J. Transpl. 14, 2037–2047 (2014).

doi: 10.1111/ajt.12847

Locke, J. E. et al. A national study of outcomes among HIV-infected kidney transplant recipients. J. Am. Soc. Nephrol. 26, 2222–2229 (2015) .

pubmed: 25791727 pmcid: 4552118 doi: 10.1681/ASN.2014070726

Camargo, J. F. et al. Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience. Clin. Transpl. 33, e13532 (2019).

doi: 10.1111/ctr.13532

Locke, J. E. et al. Survival benefit of kidney transplantation in HIV-infected patients. Ann. Surg. 265, 604–608 (2017).

pubmed: 27768622 doi: 10.1097/SLA.0000000000001761

Muller, E., Kahn, D. & Mendelson, M. Renal transplantation between HIV-positive donors and recipients. N. Engl. J. Med. 362, 2336–2337 (2010).

pubmed: 20554994 pmcid: 5094174 doi: 10.1056/NEJMc0900837

Selhorst, P. et al. Longer-term outcomes of HIV-positive-to-HIV-positive renal transplantation. N. Engl. J. Med. 381, 1387–1389 (2019).

pubmed: 31577883 pmcid: 10014633 doi: 10.1056/NEJMc1903013

Muller, E. & Barday, Z. HIV-positive kidney donor selection for HIV-positive transplant recipients. J. Am. Soc. Nephrol. 29, 1090–1095 (2018).

pubmed: 29330339 pmcid: 5875954 doi: 10.1681/ASN.2017080853

Durand, C. M. et al. A prospective multicenter pilot study of HIV-positive deceased donor to HIV-positive recipient kidney transplantation: HOPE in action. Am. J. Transpl. 21, 1754–1764 (2021).

doi: 10.1111/ajt.16205

Frassetto, L. et al. Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. Biopharm. Drug. Dispos. 34, 442–451 (2013).

pubmed: 24030928 pmcid: 4018225 doi: 10.1002/bdd.1860

Flentge, C. A. et al. Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs. Bioorg. Med. Chem. Lett. 19, 5444–5448 (2009).

pubmed: 19679477 doi: 10.1016/j.bmcl.2009.07.118

Hearps, A. C. et al. HIV infection and aging of the innate immune system. Sex. Health 8, 453–464 (2011).

pubmed: 22127030 doi: 10.1071/SH11028

Touzot, M. et al. Renal transplantation in HIV-infected patients: the Paris experience. Am. J. Transpl. 10, 2263–2269 (2010).

doi: 10.1111/j.1600-6143.2010.03258.x

Rodrigo, E. et al. Heterogeneity of induction therapy in Spain: changing patterns according to year, centre, indications and results. NDT Plus 3, ii9–ii14 (2010).

pubmed: 20508860 pmcid: 2875043

Chin-Hong, P. V. & Kwak, E. J. AST infectious diseases community of practice. human papillomavirus in solid organ transplantation. Am. J. Transpl. 13, 189–200 (2013).

doi: 10.1111/ajt.12142

Jotwani, V., Li, Y., Grunfeld, C., Choi, A. I. & Shlipak, M. G. Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors. Am. J. Kidney Dis. 59, 628–635 (2012).

pubmed: 22206742 doi: 10.1053/j.ajkd.2011.10.050

Ryom, L. et al. Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe. HIV Med. 14, 503–508 (2013).

pubmed: 23590641 doi: 10.1111/hiv.12038

Muzaale, A. D. et al. Risk of end-stage renal disease in HIV-positive potential live kidney donors. Am. J. Transpl. 17, 1823–1832 (2017).

doi: 10.1111/ajt.14235

Grupper, A. et al. In sickness and in health: living HIV positive kidney donation from a wife to her husband, with 7 years’ post-transplant follow-up. Transpl. Infect. Dis. 21, e13171 (2019).

pubmed: 31518477 doi: 10.1111/tid.13171

Johns Hopkins Medicine. First living donor HIV-to-HIV kidney transplant in the U.S. https://www.hopkinsmedicine.org/news/newsroom/news-releases/first-ever-living-donor-hiv-to-hiv-kidney-transplant-in-the-US (2019).

Kapuriya, M., Vaidya, A. & Rajkumar, V. Successful HIV-positive, live renal donor transplant. a unique method of expanding the donor pool. Transplantation 104, e140–e141 (2020).

pubmed: 31895343 doi: 10.1097/TP.0000000000003093

Saldanha, N. et al. A preemptive living donor renal transplant in an HIV positive patient from an HIV positive donor. Indian J. Nephrol. 32, 375–377 (2022).

pubmed: 35967535 pmcid: 9365000 doi: 10.4103/ijn.ijn_229_21

Doshi, M. D. et al. APOL1 genotype and renal function of black living donors. J. Am. Soc. Nephrol. 29, 1309–1316 (2018).

pubmed: 29339549 pmcid: 5875947 doi: 10.1681/ASN.2017060658

Reeves-Daniel, A. M. et al. The APOL1 gene and allograft survival after kidney transplantation. Am. J. Transpl. 11, 1025–1030 (2011).

doi: 10.1111/j.1600-6143.2011.03513.x

Okumi, M. et al. ABO-incompatible living kidney transplants: evolution of outcomes and immunosuppressive management. Am. J. Transpl. 16, 886–896 (2016).

doi: 10.1111/ajt.13502

Katou, S. et al. ABO-incompatible living donor kidney transplantation in a human immunodeficiency virus-positive recipient from a human immunodeficiency virus-positive donor: a case report. Transpl. Proc. 52, 2739–2741 (2020).

doi: 10.1016/j.transproceed.2020.07.008

Campara, M. et al. ABO incompatible renal transplantation in an HIV-seropositive patient. Transplantation 86, 176–178 (2008).

pubmed: 18622297 doi: 10.1097/TP.0b013e31817cf403

Thornton, J. Expanding HIV-positive organ donation. Lancet 397, 184–185 (2021).

pubmed: 33453770 doi: 10.1016/S0140-6736(21)00084-2

Botha, J. et al. Living donor liver transplant from an HIV-positive mother to her HIV-negative child: opening up new therapeutic options. AIDS 32, F13–F19 (2018).

pubmed: 30281558 doi: 10.1097/QAD.0000000000002000

Pereira, M. R. et al. HIV transmission through living donor kidney transplant: an 11-year follow-up on the recipient and donor. Transpl. Infect. Dis. 23, e13691 (2021).

pubmed: 34265862 doi: 10.1111/tid.13691

Lin, S.-N. et al. Outcomes of solid organ transplantation from an HIV positive donor to negative recipients. Am J Transplant. https://atcmeetingabstracts.com/abstract/outcomes-of-solid-organ-transplantation-from-an-hiv-positive-donor-to-negative-recipients (2016).

Mukhopadhyay, P. et al. Transmission of human immunodeficiency virus infection by renal transplantation. Indian. J. Nephrol. 22, 133–135 (2012).

pubmed: 22787317 pmcid: 3391812 doi: 10.4103/0971-4065.97135

Borchi, B. et al. Case report: HIV infection from a kidney transplant. Transpl. Proc. 42, 2267–2269 (2010).

doi: 10.1016/j.transproceed.2010.05.026

Fischetti, B. et al. Real-world experience with higher-than-recommended doses of lamivudine in patients with varying degrees of renal impairment. Open. Forum Infect. Dis. 5, ofy225 (2018).

pubmed: 30302352 pmcid: 6171568 doi: 10.1093/ofid/ofy225

The changing landscape of HIV-associated kidney disease.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Nina E Diana (NE)

Saraladevi Naicker (S)

Classifications MeSH